Literature DB >> 1346818

Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results.

J Convit1, C Sampson, M Zúñiga, P G Smith, J Plata, J Silva, J Molina, M E Pinardi, B R Bloom, A Salgado.   

Abstract

In an attempt to find a vaccine that gives greater and more consistent protection against leprosy than BCG vaccine, we compared BCG with and without killed Mycobacterium leprae in Venezuela. Close contacts of prevalent leprosy cases were selected as the trial population since they are at greatest risk of leprosy. Since 1983, 29,113 contacts have been randomly allocated vaccination with BCG alone or BCG plus 6 x 10(8) irradiated, autoclaved M leprae purified from the tissues of infected armadillos. We excluded contacts with signs of leprosy at screening and a proportion of those whose skin-test responses to M leprae soluble antigen (MLSA) were 10 mm or more (positive reactions). By July, 1991, 59 postvaccination cases of leprosy had been confirmed in 150,026 person-years of follow-up through annual clinical examinations of the trial population (31 BCG, 28 BCG/M leprae). In the subgroup for which we thought an effect of vaccination was most likely (onset more than a year after vaccination, negative MLSA skin-test response before vaccination), leprosy developed in 11 BCG recipients and 9 BCG/M leprae recipients; there were 18% fewer cases (upper 95% confidence limit [CL] 70%) in the BCG/M leprae than in the BCG alone group. For all cases with onset more than a year after vaccination irrespective of MLSA reaction the relative efficacy was 0% (upper 95% CL 54%; 15 cases in each vaccine group). Retrospective analysis of data on the number of BCG scars found on each contact screened suggested that BCG alone confers substantial protection against leprosy (vaccine efficacy 56%, 95% CL 27-74%) and there was a suggestion that several doses of BCG offered additional protection. There is no evidence in the first 5 years of follow-up of this trial that BCG plus M leprae offers substantially better protection against leprosy than does BCG alone, but the confidence interval on the relative efficacy estimate is wide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346818     DOI: 10.1016/0140-6736(92)91056-e

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  25 in total

1.  Controlling leprosy.

Authors:  C Lienhardt; P E Fine
Journal:  BMJ       Date:  1992-07-25

Review 2.  Leprosy as a genetic disease.

Authors:  Andrea Alter; Audrey Grant; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  Mamm Genome       Date:  2010-10-09       Impact factor: 2.957

3.  Controlling leprosy.

Authors:  C L Crawford
Journal:  BMJ       Date:  1992-09-26

4.  Effects of BCG Vaccination on Evolution of Leprosy.

Authors:  P Ramadasan; A L Das; A K Patra
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 5.  Recent advances in tropical medicine.

Authors:  D N Lockwood; G Pasvol
Journal:  BMJ       Date:  1994-06-11

6.  Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts.

Authors:  Isabela M B Goulart; Dulcinéa O Bernardes Souza; Carolina R Marques; Vânia L Pimenta; Maria A Gonçalves; Luiz R Goulart
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

7.  Antigen-specific T-cell responses of leprosy patients.

Authors:  Malcolm S Duthie; Wakako Goto; Greg C Ireton; Stephen T Reece; Lucas H Sampaio; A B Grassi; Ana Lucia M Sousa; Celina M T Martelli; Mariane M A Stefani; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

8.  Identification and characterization of epitopes shared between the mycobacterial 65-kilodalton heat shock protein and the actively secreted antigen 85 complex: their in situ expression on the cell wall surface of Mycobacterium leprae.

Authors:  A Rambukkana; P K Das; J D Burggraaf; W R Faber; P Teeling; S Krieg; J E Thole; M Harboe
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 9.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

10.  Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads.

Authors:  R H Gelber; V Mehra; B Bloom; L P Murray; P Siu; M Tsang; P J Brennan
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.